- /
- Supported exchanges
- / US
- / TEVA.NYSE
Teva Pharma Industries Ltd ADR (TEVA NYSE) stock market data APIs
Teva Pharma Industries Ltd ADR Financial Data Overview
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Teva Pharma Industries Ltd ADR (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Teva Pharma Industries Ltd ADR data using free add-ons & libraries
Get Teva Pharma Industries Ltd ADR Fundamental Data
Teva Pharma Industries Ltd ADR Fundamental data includes:
- Net Revenue: 17 230 M
- EBITDA: 4 405 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Teva Pharma Industries Ltd ADR Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-11-03
- EPS/Forecast: 0.7
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Teva Pharma Industries Ltd ADR News
New
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights: Innovative ...
This article first appeared on GuruFocus. Revenue: $4.4 billion, down 2% year-over-year in both USD and local currency. Gross Margin: Non-GAAP gross margin of 58.7%, up 245 basis points (CEO cited 34...
Teva Pharmaceutical Industries Limited’s (TEVA) Innovative Brands Drive Stronger Growth
Baron Capital, an investment management company, released its Q3 2026 investor letter for the "Baron Health Care Fund". The letter can be downloaded here. During the quarter ended September 30, 2026, ...
Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
Teva Pharmaceutical Industries Limited TEVA reported third-quarter 2026 adjusted earnings of 86 cents per share, which beat the Zacks Consensus Estimate of 72 cents. Adjusted earnings increased 10.2% ...
Teva outlines 2026 EPS of $1.92-$2.11 while projecting biosimilars to reach $800M sales in 2026
Earnings Call Insights: Teva Pharmaceutical Industries Limited (TEVA) Q3 2026 MANAGEMENT VIEW * "AUSTEDO, AJOVY and UZEDY all delivering strong Q3 performance and our innovative portfolio is up 33...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.